Rising Measles And Chickenpox Cases Drive Growth In The Market: Major Factor in the Transformation of the Proquad Market in 2025

What Is the Expected Size and Growth Rate of the Proquad Market?
In recent years, the market size for proquad has experienced a $XX (CAGR). This market is projected to expand from $XX million in 2024 to $XX million in 2025, indicating a compound annual growth rate (CAGR) of $XX%. Factors such as well-established immunization schedules, the benefits of combination vaccines, epidemic outbreaks, robust healthcare systems, government-backed vaccination initiatives, and regulatory sanctioning have contributed to the growth observed in the historic period.

In the coming years, the market size of Proquad is anticipated to experience a $XX (CAGR) growth. It is projected to escalate to a value of $XX million in 2029, posting a compound annual growth rate (CAGR) of $XX%. This upward trend during the forecast period is ascribed to factors such as population growth, improved healthcare accessibility, global health strategies, heightened awareness about vaccines for preventable diseases, government support for vaccinations and a heightened emphasis on preventive healthcare. Some of the key trends witnessed during the forecast period encompass global vaccination reach, technological improvements in vaccine distribution, incorporation of vaccines into routine healthcare systems, enhancements in vaccine availability, and escalated consciousness regarding vaccine safety.

What Factors Are Fueling Growth in the Proquad Market?
The growth of the proquad market is anticipated to be fueled by the escalating number of measles and chickenpox cases. Measles is an extremely infectious viral disease, which can be prevented with immunization, and exhibits symptoms of fever, cough and a red rash. Chickenpox, on the other hand, is an infectious ailment triggered by the Varicella-zoster virus, resulting in a rash filled with itchy blisters, and can also be prevented using a vaccine. The increased rate of measles and chickenpox cases is due to a drop in vaccination rates, inaccurate vaccine information, a rise in global travel, and disease outbreaks in non-vaccinated individuals, all contributing to the resurgence of these preventable diseases. Proquad is a combination vaccine that offers protection against measles, mumps, rubella, and varicella (chickenpox) through a single dose, lowering the chance of infection, managing disease outbreaks, and ensuring comprehensive protection to prevent associated complications. As a case in point, during the first three months of 2024, the World Health Organization, a non-profit based in Switzerland, officially reported 56,634 measles cases and four fatalities across 45 out of 53 countries in the WHO European Region. Likewise, in 2023, 41 countries reported 61,070 cases and 13 deaths. Therefore, the surge in measles and chickenpox cases is propelling the growth of the proquad market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp

Which Leading Companies Are Shaping the Growth of the Proquad Market?
Major companies operating in the proquad market are Merck and Co. Inc.

What Are the Major Trends Shaping the Proquad Market?
One significant trend in the proquad market involves increasing the range of vaccine administration options like Intramuscular (IM) administration, to improve uniformity in immunization habits and enhance comfort. The Intramuscular (IM) administration entails the direct insertion of a vaccine or drug into muscle tissue, which accelerates absorption into the bloodstream. For example, in March 2023, the U.S. pharmaceutical company Merck & Co. Inc. received approval from the U.S. Food and Drug Administration (FDA) to include an intramuscular (IM) administration option in the U.S. Product Insert (USPI) for their MMRV vaccines, including ProQuad. This approval allows the MMRV vaccines to be part of the group of preferred vaccines that could be intramuscularly administered. This provides healthcare professionals in the U.S. with the choice to give all the recommended pediatric vaccines in the CDC immunization schedule via the same IM route. ProQuad, M-M-R II, and VARIVAX are the only approved IM administration vaccines for measles, mumps, rubella, and varicella in the U.S. Additionally, the MMRV vaccines are also authorized for IM use in the European Union.

What Are the Key Segments of the Proquad Market?
The proquad market covered in this report is segmented -

1) By Indication: Measles; Mumps; Rubella; Varicella
2) By Patient Type: Pediatric Patient; Adult Patient
3) By End User: Healthcare Providers; Pharmacies; Public Health Organization

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

Which Region Dominates the Proquad Market?
North America was the largest region in the proquad market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Proquad Global Market Report?

- Market Size Analysis: Analyze the proquad Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the proquad Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall proquad market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the proquad market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20349

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.